50mins - Expert presentations By Centers for Disease Control and Prevention
Zika Virus—What Clinicians Need to Know
Experts from the CDC present a comprehensive overview: Zika Virus-What Clinicians Need to Know, and provide responses to selected questions
16mins - Expert presentations By Ahmed Elsharkawy
Management of HCV in CKD patients
In this expert presentation consultant hepatologist Dr Ahmed Elsharkawy discusses the current recommendations for patients with kidney disease and HCV. Using a case study, he explains what HCV monitoring is required in patients on renal replacement therapy and on dialysis. The HCV treatments to be offered and their evidence of efficacy is also described. Dr Elsharkawy concludes with practical take-home messages to summarize his presentation.
13mins - Expert presentations By Daniel Forton
Real-world effectiveness and safety data in HCV therapy
Dr Daniel Forton, consultant hepatologist at St George’s University Hospitals NHS Foundation Trust, London, reviews the treatment of hepatitis C, especially Direct Acting Antiviral regimes and the importance of real-world data to inform optimal selection of treatments for specific patient groups. He concludes that real-world data suggest there is still a need to tailor treatment duration with the addition of ribavirin in certain situations with certain regimes to optimise efficacy.
10mins - Expert presentations By Graham R Foster
HCV treatment in migrants, prisoners, MSMs
Professor Graham Foster, Professor of Hepatology at Queen Mary University of London, reviews the prevalance of hepatitis C among different communities as well as common treatment barriers and practial solutions. He concludes that modern-day medicine enables a variety of populations to clear viral liver disease, but highlights the challenges of engaging populations such as immigrants, MSMs and prisoners in to hepatitis C therapy.
13mins - Expert presentations By Graham R Foster
HCV treatment in children, adolescents, women and elderly
Professor Graham Foster, Professor of Hepatology at Queen Mary University of London, reviews the safety and efficacy of antivirals for the treatment of HCV infection in children, adolescents, women and elderly patients. He concludes that therapy is likely to be efficacious and well-tolerated with currently available agents, but highlights the importance of a personalised approach to care in all cases.
17mins - Expert presentations By David Back
Managing and monitoring of drug interactions
Professor David Back discusses challenges faced by HCPs when treating patients with hepatitis C infection with co-morbidities and co-medications. He presents a case study to illustrate the online tool developed by the University of Liverpool for the assessment of potential drug-drug interactions. Professor Back concludes that it is essential to review all co-medications (prescribed, OTC, herbals and internet) when starting or stopping treatment in people with HIV and HCV infection.
14mins - Expert presentations By John F Dillon
HCV in People Who Inject Drugs: diagnosis and cure
Professor John Dillon discusses the prevalence of hepatitis C infection in people who inject drugs (PWID) and proposes novel testing methods including use of dried blood spots and point of care testing to improve access to these high risk populations by healthcare professionals. He describes implementation of a programme in Scotland where these novel approaches increased uptake of testing and diagnosis of hepatitis C infection in PWID.
8mins - Expert presentations By Margaret O’Sullivan
Treating HCV in people who inject drugs: engaging the disengaged
Magaret O’Sullivan, Clinical Nurse SpecialistCommunity Care discusses how to engage and manage HCV infection in people who inject drugs (PWID). Only 5% of PWID attend hepatology clinics after their HCV diagnosis, To reduce global HCV deaths, the PWID population needs to be addressed, Community HCV services are an effective way to reach this vulnerable group, Learn about simple things that make the difference topeople wiht HCV infection who inject drugs.